Pandemic akin to war, lawyer tells Covid inquiry
Decisions were “finely balanced” and, with hindsight, might have been different, Fiona Scolding KC says.
Similar Posts
J&J to acquire Ambrx Biopharma, a cancer drug developer, for $2B
An entry sign to the Johnson & Johnson campus shows their logo in Irvine, California on August 28, 2019. Mark Ralston | AFP | Getty Images Johnson & Johnson on Monday said it will pay $2 billion in cash to acquire Ambrx Biopharma, a drugmaker specializing in one of the hottest areas of cancer treatment….
Obesity can be dangerous for dogs, experts warn — here’s how to help your pudgy pup lose weight
Read this article for free! Plus get unlimited access to thousands of articles, videos and more with your free account! Please enter a valid email address. By entering your email, you are agreeing to Fox News Terms of Service and Privacy Policy, which includes our Notice of Financial Incentive. To access the content, check your…
What you need to know about Covid as new variant rises
Hospital admissions have risen since the summer and a new variant is spreading. Should we be concerned?
Scabies outbreak in UK linked to drug shortages, experts confirm: ‘Progressively worse’
Read this article for free! Plus get unlimited access to thousands of articles, videos and more with your free account! Please enter a valid email address. By entering your email, you are agreeing to Fox News Terms of Service and Privacy Policy, which includes our Notice of Financial Incentive. To access the content, check your…
Obesity and Alzheimer’s drugs pack one-two punch to lift Eli Lilly
Investor optimism for Eli Lilly ‘s diabetes and obesity treatments in 2023 lifted the stock to its seventh annual gain in a row. In the new year, it should be the same old story. Shares of Eli Lilly have taken a breather over the past three months, as investors book profits in the top performer…
Citi and others are bullish on biotech, medtech and more
2023 wasn’t a good year for the health-care sector, but some investors expect it to make a comeback this year — highlighting biotech and medical tech as areas to watch. “Emerging from a poor capital raising environment in ’22-23, where early-stage biotech companies grappled to fund their Research and Development efforts amid rising interest rates,…